

**Amendments to the Claims**

The following listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (cancelled).

Claim 2 (original). Crystalline 2,5-dione-3-(1-methyl-1H-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1H-indol-3-yl]-1H-pyrrole mono-hydrochloride, a hydrate thereof, or mixtures thereof, having an X-ray diffraction pattern which comprises the following peaks:  $6.8 \pm 0.1$ ,  $10.9 \pm 0.1$ ,  $14.2 \pm 0.1$  and  $16.6 \pm 0.1^\circ$  in  $2\theta$ ; when the pattern is obtained from a copper radiation source ( $\text{CuK}\alpha$ ;  $\lambda = 1.54056 \text{ \AA}$ ).

Claims 3-14 (cancelled)

Claim 15 (previously presented). A pharmaceutical composition comprising a salt of claim 2 and a pharmaceutical carrier.

Claim 16 (cancelled)

Claim 17 (previously presented). A method of treating non-Hodgkins lymphoma which comprises administering to a mammal in need thereof an effective amount of a compound of claim 2.

Claim 18 (cancelled)

Claim 19 (previously presented). A method of treating glioblastoma which comprises administering to a mammal in need thereof an effective amount of a compound of claim 2.

Claim 20 (cancelled).

Claim 21 (previously presented). A method of treating non-small cell lung cancer which comprises administering to a mammal in need thereof an effective amount of a compound of claim 2.

Claim 22 (cancelled).